ARTICLE | Strategy
Delineating IL-2
Why autoimmune play Delinia lent itself to clean takeout by Celgene
February 3, 2017 8:31 PM UTC
While Celgene Corp. has a history of entering creative deals that enable its smaller partners to retain control over early development, Delinia Inc.’s clinically validated approach to treating autoimmune diseases, paired with preclinical proof-of-concept data, made the start-up ripe for a straightforward takeout.
It didn’t hurt that the biotech received multiple bids...
BCIQ Target Profiles